Your browser doesn't support javascript.
An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants.
Chan, Kui K; Tan, Timothy J C; Narayanan, Krishna K; Procko, Erik.
  • Chan KK; Orthogonal Biologics, Champaign, IL 61821, USA.
  • Tan TJC; Department of Biochemistry and Cancer Center at Illinois, University of Illinois, Urbana, IL 61801, USA.
  • Narayanan KK; Department of Biochemistry and Cancer Center at Illinois, University of Illinois, Urbana, IL 61801, USA.
  • Procko E; Department of Biochemistry and Cancer Center at Illinois, University of Illinois, Urbana, IL 61801, USA. procko@illinois.edu.
Sci Adv ; 7(8)2021 02.
Article in English | MEDLINE | ID: covidwho-1088182
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The spike S of SARS-CoV-2 recognizes ACE2 on the host cell membrane to initiate entry. Soluble decoy receptors, in which the ACE2 ectodomain is engineered to block S with high affinity, potently neutralize infection and, because of close similarity with the natural receptor, hold out the promise of being broadly active against virus variants without opportunity for escape. Here, we directly test this hypothesis. We find that an engineered decoy receptor, sACE22v2.4, tightly binds S of SARS-associated viruses from humans and bats, despite the ACE2-binding surface being a region of high diversity. Saturation mutagenesis of the receptor-binding domain followed by in vitro selection, with wild-type ACE2 and the engineered decoy competing for binding sites, failed to find S mutants that discriminate in favor of the wild-type receptor. We conclude that resistance to engineered decoys will be rare and that decoys may be active against future outbreaks of SARS-associated betacoronaviruses.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Protein Engineering / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 / COVID-19 Drug Treatment Topics: Variants Limits: Animals / Humans Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abf1738

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Protein Engineering / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 / COVID-19 Drug Treatment Topics: Variants Limits: Animals / Humans Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abf1738